FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estrogen receptor signaling is reprogrammed during breast tumorigenesis

(2019) David Chi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes

(2019) Elizabeth J. Adams et al.   NATURE

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

(2019) Abhijit Parolia et al.   NATURE

Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance

(2019) Yufan Zhou et al.   Nature Communications

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

(2018) Rinath Jeselsohn et al.   CANCER CELL

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

(2018) Noah Kornblum et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

(2018) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer

(2018) Darren K. Patten et al.   NATURE MEDICINE

KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function

(2018) Kinisha Gala et al.   ONCOGENE

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

(2018) Agostina Nardone et al.   BRITISH JOURNAL OF CANCER

Recurrent and functional regulatory mutations in breast cancer

(2017) Esther Rheinbay et al.   NATURE

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

(2017) Rinath Jeselsohn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer

(2017) Rinath Jeselsohn et al.   Current Oncology Reports

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

(2016) Eli M. Wallace et al.   CANCER RESEARCH

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations

(2016) Kana Tachi et al.   CANCER SCIENCE

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

(2016) L. Malorni et al.   MOLECULAR CANCER RESEARCH

Chromatin Scanning by Dynamic Binding of Pioneer Factors

(2016) Kenneth S. Zaret et al.   MOLECULAR CELL

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

(2016) Hyejin Cho et al.   NATURE

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

(2016) Akash Kumar et al.   NATURE MEDICINE

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer

(2016) Xiaoyong Fu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells

(2016) Muhammad Wasi Alam et al.   Oncotarget

Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells

(2016) Jerry H. Fuady et al.   Oncotarget

FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3

(2016) Kamila M. Jozwik et al.   Cell Reports

PI3K–mTORC2 but not PI3K–mTORC1 Regulates Transcription of HIF2A/EPAS1 and Vascularization in Neuroblastoma

(2015) Sofie Mohlin et al.   CANCER RESEARCH

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer

(2015) Giovanni Ciriello et al.   CELL

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

(2015) Richard A Moffitt et al.   NATURE GENETICS

Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer

(2015) Jun Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion

(2015) Van T. M. Nguyen et al.   Nature Communications

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

(2015) Bruno M. Simões et al.   Cell Reports

Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance

(2014) Gladys Morrison et al.   BREAST CANCER RESEARCH AND TREATMENT

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

(2014) Qin Feng et al.   CELL RESEARCH

Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression

(2014) F Chen et al.   Cell Death & Disease

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes

(2013) Warren A. Whyte et al.   CELL

Hypoxia-Inducible Factors in Physiology and Medicine

(2012) Gregg L. Semenza   CELL

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Cellular reprogramming by the conjoint action of ER , FOXA1, and GATA3 to a ligand-inducible growth state

(2011) S. L. Kong et al.   Molecular Systems Biology

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

FOXA1 is an essential determinant of ER  expression and mammary ductal morphogenesis

(2010) G. M. Bernardo et al.   DEVELOPMENT

Growth factor stimulation induces a distinct ER  cistrome underlying breast cancer endocrine resistance

(2010) M. Lupien et al.   GENES & DEVELOPMENT

FOXA1 is a key determinant of estrogen receptor function and endocrine response

(2010) Antoni Hurtado et al.   NATURE GENETICS

Histone H3K27ac separates active from poised enhancers and predicts developmental state

(2010) M. P. Creyghton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma

(2009) C. Nucera et al.   CLINICAL CANCER RESEARCH

Histone modifications at human enhancers reflect global cell-type-specific gene expression

(2009) Nathaniel D. Heintzman et al.   NATURE

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

(2008) C. J. Creighton et al.   CANCER RESEARCH

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription

(2008) Mathieu Lupien et al.   CELL